VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis

Bibliography

• Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28(1):3-9
   PubMed Web of Science ®Google Scholar
• Shedden AS. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Treat Respir Med 2005;4(6):439-46
   PubMedGoogle Scholar
• Bousquet J, Khaltaev N, Cruz AA, Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2007;28(2):145-52
   PubMed Web of Science ®Google Scholar
• Cingi C, Kayabasoglu G, Nacar A. Update on the medical treatment of allergic rhinitis. Inflamm Allergy Drug Targets 2009;8(2):96-103
   PubMedGoogle Scholar
• Baiardini I, Braido F, Tarantini F, ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008;63(6):660-9
   PubMed Web of Science ®Google Scholar
• Benninger M, Farrar JR, Blaiss M, Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104(1):13-29
   PubMed Web of Science ®Google Scholar
• Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 2003;90(6 Suppl 3):7-12
   PubMed Web of Science ®Google Scholar
• Pawankar R, Bunnag C, Chen Y, Allergic rhinitis and its impact on asthma update (ARIA 2008) – western and Asian-Pacific perspective. Asian Pac J Allergy Immunol 2009;27(4):237-43
   PubMed Web of Science ®Google Scholar
• Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004;112(3):352-63
   PubMed Web of Science ®Google Scholar
• Weiss ST. Eat dirt–the hygiene hypothesis and allergic diseases. N Engl J Med 2002;347(12):930-1
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O'Neill LAJ. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010;9:293-307
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med 2007;13(5):552-9
   PubMed Web of Science ®Google Scholar
• Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121(2):288-96
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler A, Stubner UP, A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56(6):498-505
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Woroniecki SR, A Th1 inducing adjuvant, MPL®, safely assists in reducing the length of a pollen allergy vaccination course. Allergol Immunol Clin 2002;17:39-43
   Google Scholar
• McCormack PL, Wagstaff AJ. Ultra-short-courseseasonal allergy vaccine (Pollinex Quatro). Drugs 2006;66:377-82
   Google Scholar
• DuBuske L, Frew A, Horak F, Ultra-short specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; In press
   Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, Immunotherapy with a Ragweek-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis. N Eng J Med 2006;355:1445-55
   PubMed Web of Science ®Google Scholar
• Holtick U, Scheulen ME, Bergwelt-Baildon MS, Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 2011;20(3):361-72
   PubMed Web of Science ®Google Scholar
• Casale TB, Kessler J, Romero FA. Safety of the intranasal Toll-like receptor 4 agonist CRX-675 in allergic disease. Ann Allergy Asthma Immunol 2006;97:454-6
   PubMed Web of Science ®Google Scholar
• Moller-Larsen S, Nyegaard M, Haagerup A, Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax 2008;63(12):1064-9
   PubMed Web of Science ®Google Scholar
• Sel S, Wegmann M, Sel S, Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-101. J Immun 2007;178:7805-13
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ, Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immun 2005;174:1259-68
   PubMed Web of Science ®Google Scholar
• Rudolf K, Bice DE, Hey JA, A model of allergic nasal congestion in dogs sensitized to ragweed. Am J Rhinol 2003;17:227-32
   PubMedGoogle Scholar
• Barrett EG, Rudolph K, Dietsch D, VTX-378, A novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs. JACI 2011;127(2 Suppl): abstract 268
   Web of Science ®Google Scholar
• Day JH, Horak F, Briscoe MP, The role of allergen challenge chambers in the evaluation of antiallergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6(2):31-59
   Google Scholar
• Horak F, Jager S. The Vienna Challenge Chamber (VCC) - A new method for environmental exposition. Wien Klin Woschenschr 1987;99(14):509-10
   Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, Intranasal Toll-like receptor 8 agonist (VTX-1463) significantly improves symptoms of allergic rhinitis in a randomized, placebo-controlled trial. JACI 2011:127:2(Suppl): abstract 199
   PubMed Web of Science ®Google Scholar